Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386356 | 1.00 | TRPV1 (1.00) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4384186 | 0.90 | TRPV1 (0.81) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL5128895 | 0.88 | TRPV1 (0.78) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4386354 | 0.87 | TRPV1 (0.76) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4389994 | 0.85 | TRPV1 (0.74) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4386620 | 0.85 | TRPV1 (0.73) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4426949 | 0.83 | TRPV1 (0.70) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL5934166 | 0.82 | TRPV1 (0.70) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4384181 | 0.82 | TRPV1 (0.69) | TRPV1RAB9ANPC1CASP3SENP7 | |
| SCHEMBL4425329 | 0.80 | TRPV1 (0.67) | TRPV1RAB9ANPC1CASP3SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606289-B1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-12-02 | — | — | EP | claimed |
| US-11241442-B2 | Methods of use for TRP channel antagonist-based combination cancer therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210128581-A1 | METHODS OF USE FOR TRP CHANNEL ANTAGONIST-BASED COMBINATION CANCER THERAPIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-05-06 | — | — | US | disclosed |
| US-20200129472-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIPHERAL ARTERY DISEASE | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2020-04-30 | — | — | US | disclosed |
| WO-2018165034-A1 | METHODS OF USE FOR TRP CHANNEL ANTAGONIST-BASED COMBINATION CANCER THERAPIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-09-13 | — | — | WO | disclosed |
| WO-2018148523-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIPHERAL ARTERY DISEASE | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2010-09-16 | — | — | US | disclosed |
| EP-1606289-B1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-7531558-B2 | e.g. 6-(4-Fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl)nicotinamide; vanilloid (capsaicin) receptor modulator; analgesic; chronic, neuropathic, postoperative, postrheumatoid arthritic, osteoarthritic, back, cancer, dental pain, algesia, neuralgia, migraine, neuropathies, ischaemia | GLAXO GROUP LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-7531558-B2 | e.g. 6-(4-Fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl)nicotinamide; vanilloid (capsaicin) receptor modulator; analgesic; chronic, neuropathic, postoperative, postrheumatoid arthritic, osteoarthritic, back, cancer, dental pain, algesia, neuralgia, migraine, neuropathies, ischaemia | GLAXO GROUP LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-7531558-B2 | e.g. 6-(4-Fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl)nicotinamide; vanilloid (capsaicin) receptor modulator; analgesic; chronic, neuropathic, postoperative, postrheumatoid arthritic, osteoarthritic, back, cancer, dental pain, algesia, neuralgia, migraine, neuropathies, ischaemia | GLAXO GROUP LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-20060148855-A1 | Carboxamide derivatives | GLAXO GROUP LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1606289-A1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004072069-A1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148855-A1 | Carboxamide derivatives | CNR2, CNR1, SUCNR1 | TRPV1 393/4885RAB9A 2395/4885NPC1 2461/4885 |
| US-20100234454-A1 | TREATMENT OF CNIDARIA INTOXICATION | CNR1, CNR2, AVPR1A | TRPV1 9/4885RAB9A 2819/4885NPC1 1678/4885 |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRPC4, TRPC1, TRPC3 | TRPV1 4/4885RAB9A 3934/4885NPC1 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.